IDH1 and glioblastoma: The genomic characterization of IDH wild-type GBM reveals frequent genetic alterations of key components of the growth factor receptor-PI3K-Akt signaling pathway that activates the mechanistic target of rapamycin (mTOR) signaling [46,47,48].